Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 574

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

Barnett, Anthony H, Mithal, Ambrish, Manassie, Jenny, Jones, Russell, Rattunde, Henning, Woerle, Hans J, Broedl, Uli C·2014·The Lancet Diabetes & Endocrinology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(13)70208-0

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 25

  1. 2013, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney Int Suppl, 3, 1
  2. Meyers, 2011, Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment, Postgrad Med, 123, 133, 10.3810/pgm.2011.05.2291 · DOI
  3. Coll-de-Tuero, 2012, Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area, BMC Nephrol, 13, 87, 10.1186/1471-2369-13-87 · DOI
  4. Koro, 2009, Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States, Clin Ther, 31, 2608, 10.1016/j.clinthera.2009.10.020 · DOI
  5. Schramm, 2008, Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3·3 million people, Circulation, 117, 1945, 10.1161/CIRCULATIONAHA.107.720847 · DOI · Paper page
  6. 2012, KDOQI clinical practice guideline for diabetes and CKD: 2012 update, Am J Kidney Dis, 60, 850, 10.1053/j.ajkd.2012.07.005 · DOI · Paper page
  7. DeFronzo, 2012, The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia, Diabetes Obes Metab, 14, 5, 10.1111/j.1463-1326.2011.01511.x · DOI · Paper page
  8. Grempler, 2012, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes Obes Metab, 14, 83, 10.1111/j.1463-1326.2011.01517.x · DOI · Paper page
  9. Heise, 2013, Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes, Diabetes Obes Metab, 15, 613, 10.1111/dom.12073 · DOI · Paper page
  10. Roden, 2013, Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Diabetes Endocrinol, 1, 208, 10.1016/S2213-8587(13)70084-6 · DOI · Paper page
  11. Häring, 2013, Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM), Diabetes, 62, A282
  12. Häring, 2013, Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial, Diabetes Care, 36, 3396, 10.2337/dc12-2673 · DOI · Paper page
  13. Kovacs, 2013, Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial, Diabetes Obes Metab
  14. Macha, 2013, Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment, Diabetes Obes Metab
  15. Ferrannini, 2013, A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes, Diabetes Obes Metab, 15, 721, 10.1111/dom.12081 · DOI · Paper page
  16. Rosenstock, 2013, Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia, Diabetes Obes Metab, 15, 1154, 10.1111/dom.12185 · DOI · Paper page
  17. Seman, 2013, Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects, Clinical Pharm in Drug Dev, 2, 152, 10.1002/cpdd.16 · DOI
  18. Rosenstock, 2013, Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM), Diabetes, 62, A285
  19. Scheen, 2013, Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease, Expert Opin Drug Metab Toxicol, 9, 529, 10.1517/17425255.2013.777428 · DOI · Paper page
  20. Kohan, 2013, Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control, Kidney Int
  21. Yale, 2013, Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease, Diabetes Obes Metab, 15, 463, 10.1111/dom.12090 · DOI · Paper page
  22. Cherney, 2013, The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes, Circulation
  23. Schnaper, 2013, Remnant nephron physiology and the progression of chronic kidney disease, Pediatr Nephrol
  24. Gaspari, 2013, The GFR and GFR decline cannot be accurately estimated in type 2 diabetics, Kidney Int, 84, 164, 10.1038/ki.2013.47 · DOI
  25. Rossing, 2006, Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy, Diabetes Care, 29, 1024, 10.2337/dc05-2201 · doi:10.2337/dc05-2201

Cited by

See all 574

Metadata

Authors
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2014-05
Volume
2
Issue
5
Pages
369-384
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2152413054
Cited by
574
References
4
FWCI
49.07
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(13)70208-0
The paper
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014). Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(13)70208-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.